Principal Investigator: David Lynch, MD, PhD, Children’s Hospital of Philadelphia
Sponsor: Reata Pharmaceuticals
This is a multi-site, placebo-controlled study involving an Nrf-2 activator called RTA 408, which has antioxidant and anti-inflammatory properties. Each of the subjects enrolled in part 2 of this study takes either study medication (150 mg RTA 408) or placebo. Enrollment has closed for part 2 of the study.
Previous subjects from part 1 and part 2 are now eligible to screen for the open-label extension phase.
This is the first study involving the testing of RTA 408 in people with Friedreich's ataxia.
For more information about this study, please contact the program at 267-426-7538 or email us at FAProgram@email.chop.edu.